InDex Gets Cash Boost For Phase III Ulcerative Colitis Drug
Swedish Firm's Cobitolimod Could Be A Blockbuster
Executive Summary
The Stockholm-based company is in a position to start the Phase III program for its ulcerative colitis candidate after raising over $64m in a rights issue.
You may also be interested in...
Almirall returns InDex's ulcerative colitis drug
Almirall has returned ulcerative colitis therapy Kappaproct to its originator company InDex Pharmaceuticals.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.